File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: Standard treatment for Helicobacter pylori infection is suboptimal in non-ulcer dyspepsia compared with duodenal ulcer in Chinese
  • Basic View
  • Metadata View
  • XML View
TitleStandard treatment for Helicobacter pylori infection is suboptimal in non-ulcer dyspepsia compared with duodenal ulcer in Chinese
 
AuthorsWong, WM1
Xiao, SD2
Hu, PJ3
Wang, WH1
Gu, Q1
Huang, JQ1
Xia, HHX1
Wu, SM2
Li, CJ3
Chen, MH3
Cui, Y3
Lai, KC1
Hu, WHC1
Chan, CK1
Lam, SK1
Wong, BCY1
 
Issue Date2005
 
PublisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/APT
 
CitationAlimentary Pharmacology And Therapeutics, 2005, v. 21 n. 1, p. 73-81 [How to Cite?]
DOI: http://dx.doi.org/10.1111/j.1365-2036.2004.02283.x
 
AbstractBackground: Recent studies suggest that the Helicobacter pylori eradication rate in patients with non-ulcer dyspepsia is lower when compared to patients with peptic ulcer diseases. Aim: The aim of this study was to study the efficacy of triple therapy for H. pylori infection in patients with duodenal ulcer vs. patients with non-ulcer dyspepsia. Methods: A total of 582 Chinese patients with proven H. pylori infection were recruited to receive: omeprazole 20 mg, amoxicillin 1000 mg and clarithromycin 500 mg all given twice daily for 7 days (OCA regime). Endoscopy with rapid urease test, histology and culture were performed before treatment. Post-treatment H. pylori status was determined by 13C-urea breath test. Metronidazole, clarithromycin and amoxicillin resistance was defined as minimum inhibitory concentration (MIC) of >8 μg/mL, >1 μg/mL and >1 μg/mL, respectively. Results: A significantly higher (intention-to-treat/per-protocol) eradication rate was found in patients with duodenal ulcer than those with non-ulcer dyspepsia (91/94% vs. 84/88% respectively, P = 0.011 and P = 0.016). Clarithromycin resistance rate was higher in patients with non-ulcer dyspepsia than those with duodenal ulcer (14% vs. 6%, P = 0.015). Clarithromycin resistance (40% vs. 5%, P < 0.001, OR 12. 95% CI: 5.7-24.3) and the diagnosis of non-ulcer dyspepsia (91% vs. 84%, P = 0.011. OR 2.0. 95% CI: 1.2-3.3) significantly affected the success of H. pylori eradication. Conclusion: Clarithromycin resistance accounts for the significantly lower and suboptimal H. pylori eradication rate of OCA regimen in Chinese patients with non-ulcer dyspepsia compared to those with duodenal ulcer.
 
ISSN0269-2813
2012 Impact Factor: 4.548
2012 SCImago Journal Rankings: 1.689
 
DOIhttp://dx.doi.org/10.1111/j.1365-2036.2004.02283.x
 
ReferencesReferences in Scopus
 
DC FieldValue
dc.contributor.authorWong, WM
 
dc.contributor.authorXiao, SD
 
dc.contributor.authorHu, PJ
 
dc.contributor.authorWang, WH
 
dc.contributor.authorGu, Q
 
dc.contributor.authorHuang, JQ
 
dc.contributor.authorXia, HHX
 
dc.contributor.authorWu, SM
 
dc.contributor.authorLi, CJ
 
dc.contributor.authorChen, MH
 
dc.contributor.authorCui, Y
 
dc.contributor.authorLai, KC
 
dc.contributor.authorHu, WHC
 
dc.contributor.authorChan, CK
 
dc.contributor.authorLam, SK
 
dc.contributor.authorWong, BCY
 
dc.date.accessioned2012-09-05T05:24:24Z
 
dc.date.available2012-09-05T05:24:24Z
 
dc.date.issued2005
 
dc.description.abstractBackground: Recent studies suggest that the Helicobacter pylori eradication rate in patients with non-ulcer dyspepsia is lower when compared to patients with peptic ulcer diseases. Aim: The aim of this study was to study the efficacy of triple therapy for H. pylori infection in patients with duodenal ulcer vs. patients with non-ulcer dyspepsia. Methods: A total of 582 Chinese patients with proven H. pylori infection were recruited to receive: omeprazole 20 mg, amoxicillin 1000 mg and clarithromycin 500 mg all given twice daily for 7 days (OCA regime). Endoscopy with rapid urease test, histology and culture were performed before treatment. Post-treatment H. pylori status was determined by 13C-urea breath test. Metronidazole, clarithromycin and amoxicillin resistance was defined as minimum inhibitory concentration (MIC) of >8 μg/mL, >1 μg/mL and >1 μg/mL, respectively. Results: A significantly higher (intention-to-treat/per-protocol) eradication rate was found in patients with duodenal ulcer than those with non-ulcer dyspepsia (91/94% vs. 84/88% respectively, P = 0.011 and P = 0.016). Clarithromycin resistance rate was higher in patients with non-ulcer dyspepsia than those with duodenal ulcer (14% vs. 6%, P = 0.015). Clarithromycin resistance (40% vs. 5%, P < 0.001, OR 12. 95% CI: 5.7-24.3) and the diagnosis of non-ulcer dyspepsia (91% vs. 84%, P = 0.011. OR 2.0. 95% CI: 1.2-3.3) significantly affected the success of H. pylori eradication. Conclusion: Clarithromycin resistance accounts for the significantly lower and suboptimal H. pylori eradication rate of OCA regimen in Chinese patients with non-ulcer dyspepsia compared to those with duodenal ulcer.
 
dc.description.natureLink_to_OA_fulltext
 
dc.identifier.citationAlimentary Pharmacology And Therapeutics, 2005, v. 21 n. 1, p. 73-81 [How to Cite?]
DOI: http://dx.doi.org/10.1111/j.1365-2036.2004.02283.x
 
dc.identifier.citeulike74115
 
dc.identifier.doihttp://dx.doi.org/10.1111/j.1365-2036.2004.02283.x
 
dc.identifier.epage81
 
dc.identifier.hkuros97002
 
dc.identifier.issn0269-2813
2012 Impact Factor: 4.548
2012 SCImago Journal Rankings: 1.689
 
dc.identifier.issue1
 
dc.identifier.pmid15644048
 
dc.identifier.scopuseid_2-s2.0-20244380121
 
dc.identifier.spage73
 
dc.identifier.urihttp://hdl.handle.net/10722/162851
 
dc.identifier.volume21
 
dc.languageeng
 
dc.publisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/APT
 
dc.publisher.placeUnited Kingdom
 
dc.relation.ispartofAlimentary Pharmacology and Therapeutics
 
dc.relation.referencesReferences in Scopus
 
dc.rightsAlimentary Pharmacology and Therapeutics. Copyright © Blackwell Publishing Ltd.
 
dc.subject.meshAdolescent
 
dc.subject.meshAdult
 
dc.subject.meshAged
 
dc.subject.meshAmoxicillin - Therapeutic Use
 
dc.subject.meshAnti-Ulcer Agents - Therapeutic Use
 
dc.subject.meshAsian Continental Ancestry Group - Ethnology
 
dc.subject.meshClarithromycin - Therapeutic Use
 
dc.subject.meshDrug Resistance
 
dc.subject.meshDrug Therapy, Combination - Therapeutic Use
 
dc.subject.meshDuodenal Ulcer - Ethnology - Microbiology
 
dc.subject.meshDyspepsia - Ethnology - Microbiology
 
dc.subject.meshFemale
 
dc.subject.meshHelicobacter Infections - Drug Therapy - Ethnology
 
dc.subject.meshHelicobacter Pylori
 
dc.subject.meshHumans
 
dc.subject.meshMale
 
dc.subject.meshMetronidazole - Therapeutic Use
 
dc.subject.meshMiddle Aged
 
dc.subject.meshOmeprazole - Therapeutic Use
 
dc.subject.meshPatient Compliance
 
dc.subject.meshTreatment Outcome
 
dc.titleStandard treatment for Helicobacter pylori infection is suboptimal in non-ulcer dyspepsia compared with duodenal ulcer in Chinese
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Wong, WM</contributor.author>
<contributor.author>Xiao, SD</contributor.author>
<contributor.author>Hu, PJ</contributor.author>
<contributor.author>Wang, WH</contributor.author>
<contributor.author>Gu, Q</contributor.author>
<contributor.author>Huang, JQ</contributor.author>
<contributor.author>Xia, HHX</contributor.author>
<contributor.author>Wu, SM</contributor.author>
<contributor.author>Li, CJ</contributor.author>
<contributor.author>Chen, MH</contributor.author>
<contributor.author>Cui, Y</contributor.author>
<contributor.author>Lai, KC</contributor.author>
<contributor.author>Hu, WHC</contributor.author>
<contributor.author>Chan, CK</contributor.author>
<contributor.author>Lam, SK</contributor.author>
<contributor.author>Wong, BCY</contributor.author>
<date.accessioned>2012-09-05T05:24:24Z</date.accessioned>
<date.available>2012-09-05T05:24:24Z</date.available>
<date.issued>2005</date.issued>
<identifier.citation>Alimentary Pharmacology And Therapeutics, 2005, v. 21 n. 1, p. 73-81</identifier.citation>
<identifier.issn>0269-2813</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/162851</identifier.uri>
<description.abstract>Background: Recent studies suggest that the Helicobacter pylori eradication rate in patients with non-ulcer dyspepsia is lower when compared to patients with peptic ulcer diseases. Aim: The aim of this study was to study the efficacy of triple therapy for H. pylori infection in patients with duodenal ulcer vs. patients with non-ulcer dyspepsia. Methods: A total of 582 Chinese patients with proven H. pylori infection were recruited to receive: omeprazole 20 mg, amoxicillin 1000 mg and clarithromycin 500 mg all given twice daily for 7 days (OCA regime). Endoscopy with rapid urease test, histology and culture were performed before treatment. Post-treatment H. pylori status was determined by 13C-urea breath test. Metronidazole, clarithromycin and amoxicillin resistance was defined as minimum inhibitory concentration (MIC) of &gt;8 &#956;g/mL, &gt;1 &#956;g/mL and &gt;1 &#956;g/mL, respectively. Results: A significantly higher (intention-to-treat/per-protocol) eradication rate was found in patients with duodenal ulcer than those with non-ulcer dyspepsia (91/94% vs. 84/88% respectively, P = 0.011 and P = 0.016). Clarithromycin resistance rate was higher in patients with non-ulcer dyspepsia than those with duodenal ulcer (14% vs. 6%, P = 0.015). Clarithromycin resistance (40% vs. 5%, P &lt; 0.001, OR 12. 95% CI: 5.7-24.3) and the diagnosis of non-ulcer dyspepsia (91% vs. 84%, P = 0.011. OR 2.0. 95% CI: 1.2-3.3) significantly affected the success of H. pylori eradication. Conclusion: Clarithromycin resistance accounts for the significantly lower and suboptimal H. pylori eradication rate of OCA regimen in Chinese patients with non-ulcer dyspepsia compared to those with duodenal ulcer.</description.abstract>
<language>eng</language>
<publisher>Blackwell Publishing Ltd. The Journal&apos;s web site is located at http://www.blackwellpublishing.com/journals/APT</publisher>
<relation.ispartof>Alimentary Pharmacology and Therapeutics</relation.ispartof>
<rights>Alimentary Pharmacology and Therapeutics. Copyright &#169; Blackwell Publishing Ltd.</rights>
<subject.mesh>Adolescent</subject.mesh>
<subject.mesh>Adult</subject.mesh>
<subject.mesh>Aged</subject.mesh>
<subject.mesh>Amoxicillin - Therapeutic Use</subject.mesh>
<subject.mesh>Anti-Ulcer Agents - Therapeutic Use</subject.mesh>
<subject.mesh>Asian Continental Ancestry Group - Ethnology</subject.mesh>
<subject.mesh>Clarithromycin - Therapeutic Use</subject.mesh>
<subject.mesh>Drug Resistance</subject.mesh>
<subject.mesh>Drug Therapy, Combination - Therapeutic Use</subject.mesh>
<subject.mesh>Duodenal Ulcer - Ethnology - Microbiology</subject.mesh>
<subject.mesh>Dyspepsia - Ethnology - Microbiology</subject.mesh>
<subject.mesh>Female</subject.mesh>
<subject.mesh>Helicobacter Infections - Drug Therapy - Ethnology</subject.mesh>
<subject.mesh>Helicobacter Pylori</subject.mesh>
<subject.mesh>Humans</subject.mesh>
<subject.mesh>Male</subject.mesh>
<subject.mesh>Metronidazole - Therapeutic Use</subject.mesh>
<subject.mesh>Middle Aged</subject.mesh>
<subject.mesh>Omeprazole - Therapeutic Use</subject.mesh>
<subject.mesh>Patient Compliance</subject.mesh>
<subject.mesh>Treatment Outcome</subject.mesh>
<title>Standard treatment for Helicobacter pylori infection is suboptimal in non-ulcer dyspepsia compared with duodenal ulcer in Chinese</title>
<type>Article</type>
<description.nature>Link_to_OA_fulltext</description.nature>
<identifier.doi>10.1111/j.1365-2036.2004.02283.x</identifier.doi>
<identifier.pmid>15644048</identifier.pmid>
<identifier.scopus>eid_2-s2.0-20244380121</identifier.scopus>
<identifier.hkuros>97002</identifier.hkuros>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-20244380121&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>21</identifier.volume>
<identifier.issue>1</identifier.issue>
<identifier.spage>73</identifier.spage>
<identifier.epage>81</identifier.epage>
<publisher.place>United Kingdom</publisher.place>
<identifier.citeulike>74115</identifier.citeulike>
<bitstream.url>http://hub.hku.hk/bitstream/10722/162851/1/re01.htm</bitstream.url>
</item>
Author Affiliations
  1. The University of Hong Kong
  2. Shanghai Second Medical University
  3. Sun Yat Sen University of Medical Sciences